Learn more about participating in an ongoing clinical research study.
A clinical research study is underway to evaluate the effects of an investigational therapy, afamelanotide, as a treatment for vitiligo patients with darker skin types.
What is the purpose of this study?
This study is evaluating whether the investigational therapy afamelanotide, combined with narrowband ultraviolet B (NB-UVB) light treatment can improve repigmentation in vitiligo patients with darker skin types, when compared to the use of NB-UVB as a stand-alone therapy.
This study will last approximately 12 months, with up to one (1) month screening period, five (5) months of treatment and up to six (6) months of follow up. This will be followed by an extension phase for a select group of participants. Up to 200 patients with vitiligo from different countries will be enrolled to this study and randomly allocated to one of the two study groups:
- Afamelanotide in combination with NB-UVB light treatment
- NB-UVB light treatment alone
Participants who complete the NB-UVB light treatment alone may be invited to the extension phase and receive afamelanotide treatment with NB-UVB for 20 weeks.
Am I eligible?
Eligible participants:
- Have vitiligo on their face and body
- Are aged 12 or more
- Have Fitzpatrick skin types III‒VI (medium to dark skin)
- Do not have extensive white hair in your vitiligo patches (leukotrichia)
- Do not have a history of melanoma, lentigo maligna or do not have any malignant (cancerous) skin lesions
- Do not have liver diseases
- Are not pregnant or breastfeeding
Note that other criteria may apply.
All eligible participants enrolled to the study will receive NB-UVB light treatment, which is the standard of care for treating of vitiligo.
There is no cost to participate in the study and participants may be eligible for travel reimbursements.